HIA
RYTM icon

HFM Investment Advisors’s Rhythm Pharmaceuticals RYTM Stock Holding History

HFM Investment Advisors’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1
Closed -$87 – 1315
2026
Q1 		$87 Sell
1
-1
-50% -$97 ﹤0.01% 1136
2025
Q4 		$215 Buy
+2
New +$212 ﹤0.01% 1001

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

HFM Investment Advisors's RYTM Position: Q2 2026 in Review

HFM Investment Advisors sold out of Rhythm Pharmaceuticals (RYTM) in Q2 2026, closing a stake of 1 share — an estimated $87 sold.

HFM Investment Advisors first reported a position in RYTM in Q4 2025 and held it in 2 quarters. The position peaked at $215 in Q4 2025. 303 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • HFM Investment Advisors reported no remaining Rhythm Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • HFM Investment Advisors sold 1 Rhythm Pharmaceuticals share in Q2 2026, an estimated $87.
  • HFM Investment Advisors first reported a position in Rhythm Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • HFM Investment Advisors's Rhythm Pharmaceuticals position peaked at $215 in Q4 2025.
  • 303 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on HFM Investment Advisors's 13F filing for Q2 2026, filed 4 Aug 2026.